FindTrial
Sign In

PSMA-11

DRUG3 trials

Sponsors

National Cancer Institute (NCI), Advanced Accelerator Applications, Heinrich-Heine University, Duesseldorf

Conditions

Cancer Of ProstateHigh-risk Prostate CancerIntermediate-risk Prostate CancerMetastatic Castration-resistant Prostate Cancer (mCRPC)Metastatic Prostate CancerProstate CancerProstate NeoplasmsProstatic Cancer

Phase 2

18F-DCFPyL PET/CT in High Risk and Recurrent Prostate Cancer
Active, not recruitingNCT03181867
National Cancer Institute (NCI)Cancer Of Prostate, Metastatic Prostate Cancer, Prostate Cancer +2
Start: 2017-08-03End: 2031-02-01Updated: 2026-09-02

Unknown Phase

177Lu-PSMA-617 Managed Access Program for mCRPC Patients
NCT04825652
Advanced Accelerator ApplicationsMetastatic Castration-resistant Prostate Cancer (mCRPC)
Updated: 2023-01-13
COMBINED PSMA-PET/CT AND MRI STAGING IN INTERMEDIATE AND HIGH-RISK PATIENTS PROSTATA-CANCER (COMBINE-P)
Active, not recruitingNCT07455097
Heinrich-Heine University, DuesseldorfHigh-risk Prostate Cancer, Intermediate-risk Prostate Cancer
Start: 2026-01-01End: 2026-12-31Target: 600Updated: 2026-03-06

Related Papers

Linking Baseline PSMA PET-Derived Parameters to Toxicity, Adverse Events, Pain, and Quality of Life in Patients Treated with [<sup>177</sup>Lu]Lu-PSMA-617: A Single-Center Retrospective Study.
2025-12-04
Assessment of PSMA PET/CT derived predictive markers for <sup>177</sup> Lu-PSMA-617 treatment outcomes: Results from the U.S. Expanded-Access program.
Journal of Clinical Oncology2025-05-281 citations
Efficacy and Toxicity of [<sup>177</sup>Lu]Lu-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer: Results from the U.S. Expanded-Access Program and Comparisons with Phase 3 VISION Data
Journal of Nuclear Medicine2024-09-269 citations
Efficacy and toxicity of [<sup>177</sup>Lu]Lu-PSMA-617 for metastatic castration-resistant prostate cancer in a real-world setting: Results from the U.S. Expanded Access Program and comparisons with phase 3 VISION data.
Journal of Clinical Oncology2024-06-011 citations
Salivary excretion of systemically injected [18F]DCFPyL in prostate cancer patients undergoing PSMA scans
Frontiers in Oncology2024-04-23
Early outcomes from lutetium Lu-177 vipivotide tetraxetan treatment in patients selected for therapy with piflufolastat F-18 PET imaging.
Journal of Clinical Oncology2023-02-20
Pattern of failure in prostate cancer previously treated with radical prostatectomy and post-operative radiotherapy: a secondary analysis of two prospective studies using novel molecular imaging techniques.
2021-02-1012 citations